Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Arcus Biosciences, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.111 -- 00:00:05.556 Hello everyone, and thank you for joining the Arcus Biosciences full year and fourth 00:00:05.556 -- 00:00:09.401 quarter 2025 earnings and financial results call. 00:00:09.401 -- 00:00:12.585 My name is Claire and I'll be coordinating your call today. 00:00:12.585 -- 00:00:16.730 During the presentation, you can register a question by pressing star followed by one 00:00:16.730 -- 00:00:21.455 on your telephone keypad. If you change your mind, please press star followed by two 00:00:21.455 -- 00:00:26.761 on your telephone keypad. I will now hand over to Holly Colkey from Arcus Biosciences 00:00:26.761 -- 00:00:29.863 to begin. Please go ahead. 00:00:30.052 -- 00:00:34.637 Good afternoon, and thank you for joining us on today's conference call to discuss ARCIS' 00:00:34.637 -- 00:00:39.943 fourth quarter and full year 2025 financial results and pipeline updates. 00:00:39.943 -- 00:00:44.928 I will be filling in for Pia Eads, our head of IR, who is out on maternity leave. 00:00:44.928 -- 00:00:49.493 I would like to remind you that on this call, management will make forward-looking statements, 00:00:49.493 -- 00:00:54.498 including statements about our cash runway, our projected 2026 revenue, 00:00:54.498 -- 00:00:56.220 and our expected 00:00:56.220 -- 00:00:59.650 clinical development milestones and timelines. 00:00:59.650 -- 00:01:04.697 All statements, other than historical facts, reflect the current beliefs and 00:01:04.697 -- 00:01:09.725 expectations of management and involve risks and uncertainties that may cause our 00:01:09.725 -- 00:01:13.290 actual results to differ from those expressed. 00:01:13.290 -- 00:01:18.498 Those risks and uncertainties are described in our most recent annual report in Form 00:01:18.498 -- 00:01...